SCHEMBL849308

SCHEMBL849308

CNCCOCCOCCO

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.58
KMT2A Q03164 5/20 0.58
TSHR P16473 3/20 0.53
MAPK1 P28482 2/20 0.53
THRB P10828 1/20 0.44
HTT P42858 1/20 0.44
MAPT P10636 1/20 0.44
ALDH1A1 P00352 3/20 0.43
APP P05067 2/20 0.37
KCNH3 Q9ULD8 2/20 0.33
HTR1D P28221 1/20 0.32
HTR1B P28222 1/20 0.32
USP2 O75604 1/20 0.30
LMNA P02545 1/20 0.30
CYP3A4 P08684 1/20 0.30
CASP1 P29466 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
SLCO1B3 Q9NPD5 1/20 0.30
SLCO1B1 Q9Y6L6 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26068190 1.00 MEN1 (0.58) MEN1KMT2ATSHRMAPK1THRB
SCHEMBL19295220 1.00 MEN1 (0.58) MEN1KMT2ATSHRMAPK1THRB
SCHEMBL16806576 1.00 MEN1 (0.58) MEN1KMT2ATSHRMAPK1THRB
SCHEMBL30380142 1.00 MEN1 (0.58) MEN1KMT2ATSHRMAPK1THRB
SCHEMBL20548025 1.00 MEN1 (0.58) MEN1KMT2ATSHRMAPK1THRB
SCHEMBL24376233 1.00 MEN1 (0.58) MEN1KMT2ATSHRMAPK1THRB
SCHEMBL16806577 1.00 MEN1 (0.58) MEN1KMT2ATSHRMAPK1THRB
SCHEMBL21106327 1.00 MEN1 (0.58) MEN1KMT2ATSHRMAPK1THRB
SCHEMBL21069959 1.00 MEN1 (0.58) MEN1KMT2ATSHRMAPK1THRB
SCHEMBL40114 0.97

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12552783-B2 Modulators of proteolysis and associated methods of use ARVINAS OPERATIONS, INC. (US) 2026-02-17 US disclosed
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-10-23 US disclosed
EP-4613773-A2 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-09-10 EP disclosed
EP-3731869-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-07-23 EP disclosed
US-20250205344-A1 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERATIVES AS DEGRONS IN PROTACS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2025-06-26 US disclosed
US-20250177533-A1 PHOTODYNAMIC THERAPY AND DIAGNOSIS Invion Limited (AU) 2025-06-05 US disclosed
WO-2025105486-A1 ANTIBODY-PHOTOSENSITIVE SUBSTANCE CONJUGATE 第一三共株式会社 2025-05-22 WO disclosed
WO-2025080995-A1 PHARMACEUTICAL AGENT-INTEGRIN LIGAND CONJUGATES FOR MUSCLE DELIVERY ADARX PHARMACEUTICALS, INC. (US) 2025-04-17 WO disclosed
EP-4499628-A1 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERIVATIVES AS DEGRONS IN PROTACS GlaxoSmithKline Intellectual Property Development Limited (GB) 2025-02-05 EP disclosed
US-20250000985-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-01-02 US disclosed
EP-2433940-A1 SPIROIMIDAZOLONE DERIVATIVE Chugai Seiyaku Kabushiki Kaisha (JP) 2012-03-28 EP disclosed
EP-2433940-A1 SPIROIMIDAZOLONE DERIVATIVE Chugai Seiyaku Kabushiki Kaisha (JP) 2012-03-28 EP disclosed
WO-2010126030-A1 SPIROIMIDAZOLONE DERIVATIVE 中外製薬株式会社 (JP) 2010-11-04 WO disclosed
EP-0805674-B1 SKIN AND HAIR COSMETIC COMPOSITIONS KAO CORP (JP) 2003-03-12 EP disclosed
US-6348200-B1 OXYALKYLAMIDE OR AMINE DERIVATIVES;AT LEAST ONE OF POLYHYDRIC ALCOHOLS, OR VEGETABLE EXTRACTS, OR ORGANIC ACIDS; IMPROVES WATER-RETAINING ABILITY OF HORNY LAYER, CURES ROUGHNESS AND PREVENTS WRINKLES KAO CORPORATION (JP) 2002-02-19 US disclosed
US-6187955-B1 A MOISTURIZER FOR SOFTENING SKINS; USEFUL AS COMPONENTS OF COSMETIC FORMULATIONS KAO CORPORATION (JP) 2001-02-13 US disclosed
US-5723133-A GUANIDINE WITH ORGANIC ACID FOR SKIN SOFTENING KAO CORPORATION (JP) 1998-03-03 US disclosed
EP-0805674-A1 SKIN AND HAIR COSMETIC COMPOSITIONS Kao Corporation (JP) 1997-11-12 EP disclosed
WO-1997014401-A1 SKIN AND HAIR COSMETIC COMPOSITIONS KAO CORPORATION (JP) 1997-04-24 WO disclosed
WO-1991015467-A1 AMINOPOLYCARBOXYLIC ACID CHELATING AGENTS COCKBAIN, JULIAN, RODERICK, MICHAELSON (GB) 1991-10-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 MEN1 4055/4885KMT2A 445/4885TSHR 3319/4885
US-20250000985-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 MEN1 4055/4885KMT2A 445/4885TSHR 3319/4885
US-20250177533-A1 PHOTODYNAMIC THERAPY AND DIAGNOSIS PPOX, PPIF, ALAD MEN1 2849/4885KMT2A 3484/4885TSHR 4639/4885
US-20250205344-A1 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERATIVES AS DEGRONS IN PROTACS CRBN, AR, GNRHR MEN1 1265/4885KMT2A 2365/4885TSHR 1382/4885
US-12552783-B2 Modulators of proteolysis and associated methods of use CRBN, ADRM1, MDM2 MEN1 3384/4885KMT2A 1095/4885TSHR 2253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.